Clinical study of irinotecan in combination with PF in treatmeant of advanced esophageal cancer

( views:1314, downloads:0 )
ZHANG Jing-wei(Department of Oncology, Nan Yang Central Hospital,HeNan 473000, China)
DUAN Dong-mei()
REN Zhong-hai(Department of Oncology, Nan Yang Central Hospital,HeNan 473000, China)
Journal Title:
Volume 04, Issue 12, 2010
10.3760/cma.j.issn 1673-8799.2010.12.06
Key Word:
Irinotecan;Advanced esophageal cancer;Chemotherapy

Abstract: Objective To evaluate the efficacy and adverse events of irinotecan (CPT-11)combined with PF in the treatmentof patients with advanced esophageal cancer. Methods A totalof 73 cases with advanced esophageal entered this trial. The patientswere randomly divided into trial group and control group, and 37 cases received chemotherapy of PIF regimen. 36 cases received chemotherapy of PF regimen. Each patient received at least 2 cyclesof chemotherapy. Results The efficacy and adverse events were evaluated in all patients. The overall response ratewas 59.46% in the PIF group and 46. 67% in the PF group, the difference between the two groups did not reach statistical significance(P > 0. 05). The median time to progression(TTP)was 5.9 months in the PIF group and 4.4 months in the PF group. Themedian survival time(MST) was 12. 2months in the IP group and 9.3 months in the PF group. The main adverse events included elosuppression, nausea, vomiting and diarrhea. A lone diarrheawith statistically significant difference detected(P< 0. 05). Conclusion For advanced esophageal cancerpatients, PIF treatment achieves better therapeutic effects than PF treatment. it is toxicity is tolerable, It is valuable for clinical practicing.

  • [1]Muro K,Hamaguchi T,Ohtsu A,et al.A phase Ⅱ study of single agentdocetaxel in patientswith metastatic esophageal cancer.Annals of Oncology,2004,15 (6):955.
  • [2]储大同.当代肿瘤内科治疗方案评价.北京大学医学出版社,2004,7:72-73.
  • [3]王瑞林.晚期、复发转移性食管癌姑息性药物治疗进展.肿瘤基础与临床,2009,22(1):83-90.
  • [4]Ilson DH,Saltz L,Enzinqer P,et al.Phase Ⅱ trial ofweekly irinotecan plus cisp latin in advanced esophageal cancer.J Clin Oncol,1999,17 (10):3270.
  • [5]Ajani JA,Baker J,Pisters PW,et al.Mansfi eld PF,Feig BW,Charnsangavej C.CPT-11 plus cisplatinin patients with advanced,untreated gastric or gastroesophageal junction carcinoma:results of aphase Ⅱ study.Cancer,2002,94:641-646.
  • [6]MührWilkenshoff F,Hinkelbein W,Ohnesorge I,et al.Apilot of irinotecan(CPT-11)as single-agent therapy in patients with locally advanced ormetastatic esophageal carcinoma.Int J Colorectal Dis,2003,18 (4):330-334.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615